Michael Heffernan
Founder bei COLLEGIUM PHARMACEUTICAL, INC.
Vermögen: 2 Mio $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paul Wotton | M | 63 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 7 Jahre |
Gregory Bailey | M | 68 | 10 Jahre | |
Vladimir Coric | M | 53 | 9 Jahre | |
Jennifer Good | F | 59 | 13 Jahre | |
Michael Rogers | M | 64 | 8 Jahre | |
Julia Gregory | F | 71 | 7 Jahre | |
Joseph Ciaffoni | M | 53 | 7 Jahre | |
Robert Hugin | M | 69 | 4 Jahre | |
Antoine Awad | M | 44 | 6 Jahre | |
Ed Mathers Mathers | M | 64 | 12 Jahre | |
George Clark | M | - | 5 Jahre | |
Irina Antonijevic | M | 59 | 2 Jahre | |
Peter Barrett | M | 71 |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | 7 Jahre |
Steven Gilman | M | 71 | 8 Jahre | |
John Childs | M | 81 | 10 Jahre | |
Kimberly Gentile | F | 56 | 9 Jahre | |
Shirley Kuhlmann | F | 40 | 6 Jahre | |
Terrence Connolly | M | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
Douglas G. Gray | M | - | - | |
Kishan Mehta | M | 38 | 3 Jahre | |
Garen Bohlin | M | 76 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 12 Jahre |
Douglas R. Carlson | M | 45 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 2 Jahre |
Mary Dooley | F | 43 | 6 Jahre | |
Matthew Buten | M | 62 | 3 Jahre | |
Terry Connolly | F | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | 3 Jahre |
John Freund | M | 70 | 10 Jahre | |
Scott Dreyer | M | 52 | 6 Jahre | |
Mark Hensley | M | - | 8 Jahre | |
Noel Barnard | M | - | 11 Jahre | |
Myles Wolf | M | 53 | 4 Jahre | |
Rita Balice-Gordon | M | 63 | 4 Jahre | |
Thomas Sciascia | M | 70 | 13 Jahre | |
John Fallon | M | 76 | 8 Jahre | |
Gino Santini | M | 66 | 12 Jahre | |
Jennifer Porcelli | F | - | 2 Jahre | |
Brendan St Amant | M | - | 3 Jahre | |
Irfan Qureshi | M | - | - | |
Paloma Moraleda | F | - | 2 Jahre | |
Gastón Ortega | M | - | 2 Jahre | |
Scott Sudduth | M | - | 6 Jahre | |
Thomas J. Adam | M | - | 7 Jahre | |
Gwen Melincoff | M | 72 | 7 Jahre | |
Richard Shea | M | 72 | 7 Jahre | |
Dominick Colangelo | M | 60 | 4 Jahre | |
Lori Kunkel | M | 66 |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
Nick Leschly | M | 51 | 7 Jahre | |
Ronald Frieson | M | 65 | 3 Jahre | |
Adrian Adams | M | 73 | 6 Jahre | |
LeAnne M. Zumwalt | F | 65 | 3 Jahre | |
James Cassella | M | 69 | 4 Jahre | |
Thomas Holm Pedersen | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 9 Jahre |
Neil McFarlane | M | 51 | 2 Jahre | |
Anne VanLent | F | 76 | 6 Jahre | |
Megan M. Dow | M | - | 4 Jahre | |
Caroline Dircks | M | - | 4 Jahre | |
Morten Graugaard Døssing | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Rita L. Mannella | F | - | 7 Jahre | |
Sabine Dandiguian | F | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Omid Veiseh | M | - |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
Jeremy Springhorn | M | 61 |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 5 Jahre |
Scott Morenstein | M | 48 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
Katie McManus | F | - | - | |
Josh Richardson | M | 42 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
Ulf Meier-Kriesche | M | - | 7 Jahre | |
Thomas J. O'Brien | M | 75 |
University of Connecticut
| 38 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Mette Agger | F | 59 | 9 Jahre | |
Craig Collard | M | 58 | 13 Jahre | |
Alastair Stuart McEwan | M | 69 | 3 Jahre | |
Michael Tarnok | M | 69 | 9 Jahre | |
Jodie Morrison | F | 48 | 4 Jahre | |
Ira Duarte | F | 55 | 7 Jahre | |
Johnny Stilou | M | 57 | 8 Jahre | |
Jeffrey M. Nugent | M | 76 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 4 Jahre |
Aoife Brennan | M | 48 | 8 Jahre | |
Gary H. Rabin | M | 58 | 7 Jahre | |
Gregory Madison | M | 57 | 4 Jahre | |
Eran Nadav | M | 55 | 7 Jahre | |
Mark Enyedy | M | 60 | 4 Jahre | |
David Spellman | M | 48 | 3 Jahre | |
John D. Weinberg | M | 57 | 6 Jahre | |
Masao Yoshida | M | - | - | |
Elyse Stock | M | 66 | 5 Jahre | |
Jason Amello | M | 55 | 7 Jahre | |
Michael P. Culmo | M | - |
University of Connecticut
| 6 Jahre |
Edward Myles | M | 52 | 3 Jahre | |
Scott A. Holmes | M | 50 | 3 Jahre | |
Declan Doogan | M | 72 | 8 Jahre | |
Jane C. I. Hirsh | F | - |
Onset Dermatologics LLC
Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | - |
Patrick Heron | M | 53 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 8 Jahre |
Mark C. Boelhouwer | M | - |
University of Connecticut
| 2 Jahre |
Amy Sullivan | F | 54 | 4 Jahre | |
Enrico Picozza | M | 64 |
University of Connecticut
| 4 Jahre |
Eric Aguiar | M | 62 | 4 Jahre | |
Brian Adams | M | 50 | 4 Jahre | |
James Engelhart | M | 60 | 5 Jahre | |
Charles Conway | M | 62 | 5 Jahre | |
John Tilton | M | 56 | 6 Jahre | |
David Durgin Wharmby | M | - |
University of Connecticut
| 17 Jahre |
Raimonds Dzelme | M | - | - | |
Maxine Gowen | M | 66 | 7 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 68 | 68,00% |
Dänemark | 15 | 15,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Heffernan
- Persönliches Netzwerk